ArticleJournal for immunotherapy of cancer2022
FimH confers mannose-targeting ability to Bacillus Calmette-Guerin for improved immunotherapy in bladder cancer.
Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- ELISPOT as a Functional for Biomarker Study in Cancer Immunotherapy: Applications and Future Directions.International journal of molecular sciences · 2026Pooled it
- Modification-Selective Inhibition of Succinate Dehydrogenase a Enables Tumor-Restricted Mitochondrial Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Identification and evaluation of tumor pyroptosis-associated antigens for design a vaccine candidate against lung cancer.Scientific reports · 2026Article
- Octopus-inspired engineered bacteria with a plug-and-play surface display system achieves enhanced tumor-specific colonization and antitumor immunity.Military Medical Research · 2026Article
- BCG therapy in bladder cancer and its tumor microenvironment interactions.Clinical microbiology reviews · 2025Review
- TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity.NPJ vaccines · 2025Article
- Advances in recombinant Bacillus Calmette-Guérin therapy for bladder cancer from 2015 to 2024: Innovations and challenges.Bladder (San Francisco, Calif.) · 2025Review
- Bladder cancer immunotherapy parallel advances in BCG optimization and next-generation vaccine platforms.Frontiers in immunology · 2025Review
- Escherichia coli on colorectal cancer: A two-edged sword.Microbial biotechnology · 2024Review
- Synergistic intravesical instillation for bladder cancer: CRISPR-Cas13a and fenbendazole combination therapy.Journal of experimental & clinical cancer research : CR · 2024Article
- Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment.Journal of Zhejiang University. Science. B · 2024Review
- Immunoinformatics and computational approaches driven designing a novel vaccine candidate against Powassan virus.Scientific reports · 2024Article
- Revolutionizing Nipah virus vaccinology: insights into subunit vaccine development strategies and immunological advances.In silico pharmacology · 2024Article
- Immunoinformatics-aided rational design of a multi-epitope vaccine targeting feline infectious peritonitis virus.Frontiers in veterinary science · 2023Article
- Efficient Delivery of P3H4 siRNA and Chlorin e6 by cRGDfK-Installed Polyarginine Nanoparticles for Tumor-Targeting Therapy of Bladder Cancer.Pharmaceutics · 2022Article
- BCG in Bladder Cancer Immunotherapy.Cancers · 2022Review
- Clinical value of M1 macrophage-related genes identification in bladder urothelial carcinoma andFrontiers in genetics · 2022Article
- High mannose level in bladder cancer enhances type 1 fimbria-mediated attachment of uropathogenicFrontiers in cellular and infection microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundBladder cancer is a common disease worldwide with most patients presenting with the non-muscle-invasive form (NMIBC) at initial diagnosis. Postoperational intravesical instillation of BCG is carried out for patients with high-risk disease to reduce tumor recurrence and progression to muscle invasive disease. However, BCG can also have side effects or be ineffective in some patients because it cannot enter the cancer cells. Thus, to improve the efficacy of BCG immunotherapy is the long-term pursuit of the bladder cancer field.
methodsTo increase the adhesion of BCG to the urothelium we overexpressed FimH, a mannose binding protein naturally used by uropathogenic
resultsrBCG-S.FimH exhibited markedly improved adhesion and more rapid internalization into urothelial cells than wild-type BCG, resulting in more potent antitumor activity in orthotopic murine models of bladder cancer. To our surprise, rBCG-S.FimH elicited a much more prominent Th1-biased immune response known to be positively correlated with BCG efficacy. Mechanistic studies using TLR4 knockout mouse showed that rBCG-S.FimH could induce enhanced dendritic cell activation and tumor antigen-specific immune response in a TLR4-dependent manner. Furthermore, human peripheral blood mononuclear cells stimulated by rBCG-S.FimH also showed better tumoricidal effects than those using wild-type BCG.
conclusionrBCG-S.FimH is a novel BCG strain with significantly improved efficacy against bladder cancer. Since intravesical BCG immunotherapy is the first-line treatment for NMIBC, which accounts for more than 70% of all bladder cancer cases, our results provide a compelling rationale for clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.